Upgrade to SI Premium - Free Trial

AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'

August 11, 2026 7:07 AM
(Updated - August 11, 2026 9:40 AM EDT)

Truist Securities analyst Srikripa Devarakonda raised the price target on AbCellera ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change